Evaluating of colchicine use patterns and attack frequency of familial Mediterranean fever patients in the COVID-19 pandemic

Familial Mediterranean Fever (FMF) is an autosomal recessive and dominant inherited disease and is the most common autoinflamma-tory disease characterized by recurrent episodes of fever, arthritis, and polyserositis.1Colchicine is the main therapeutic agent used in FMF patients.2,3It reduces attacks, improves quality of life, and most importantly, prevents amyloidosis.3 The lifetime use of colchicine is recom-mended in individuals with M694V homozygous variant or com-pound heterozygous with other pathogenic variants.